Staff Profile
Background
Qualifications:
- BSc (Hons) in Biochemistry (First Class) - Lancaster University - 2016
- MRes in Biosciences (Merit) - Newcastle University - 2017
- PhD in Molecular Oncology - Paediatric Brain Tumour Group, Newcastle University - 2022
Positions:
- 2021 to Present - Post-Doctoral Research Associate - Solid Tumour Target Discovery lab, Newcastle University
Research
I am a research associate working in the Coffey lab as part of the urology collaborative research group, located within the Biosciences Institute and the Newcastle University Cancer Centre. My postdoctoral research is focussed on characterising kinase signalling pathways and how these can be therapeutically targeted to provide new therapies for prostate cancer patients.
Research Interests:
- Kinase signalling activity in prostate cancer
- Design and optimisation of antibody panels for imaging mass cytometry
- Optimisation of ex vivo prostate tissue slice culture (in collaboration with Dr Stuart McCracken)
Expertise:
- Bioinformatics: HiC, RNA-seq, ChIP-seq, Imaging mass cytometry data (R, Linux, Python)
- Imaging techniques: Immunofluorescence, Imaging mass cytometry
- Ex vivo culture
- Chromatin immunoprecipitation
- Mammalian tissue culture
- Bacterial culture
- Cloning
- Basic wet lab techniques: western blot, Real-time PCR
Publications
-
Article
- Alebady ZAH, Azizyan M, Nakjang S, Lishman-Walker E, Al-Kharaif D, Walker S, Choo HX, Garnham R, Scott E, Johnson KL, Robson CN, Coffey K. CDC20 is regulated by the histone methyltransferase, KMT5A, in castration resistant prostate cancer. Cancers 2023, 15(14), 3597.
-
Review
- Lishman-Walker E, Coffey K. Casein Kinase 1α—A Target for Prostate Cancer Therapy?. Cancers 2024, 16(13), 2436.